Safety of Almonertinib Clinical Trial
Official title:
An Open, Multicenter Phase II Clinical Study to Evaluate the Safety and Efficacy of Almonertinib in Patients With Advanced NSCLC With Rare Mutations in EGFR
This is a multicenter, open, phase II clinical trial evaluating the safety and efficacy of high-dose almonertinib in the treatment of rare mutations in locally advanced or metastatic NSCLC patients with EGFR mutations (excluding exon 19 deletion or rare mutations outside L858R). Patients showed EGFR mutations by tissue or blood tests (excluding exon 19 deletion or rare mutations other than L858R), of which 20 exon (20INS) mutations and rare mutations other than 20Ins were classified as two covariates. High-dose amitinib was used for treatment to evaluate the safety and efficacy of the treatment regimen.
n/a